Investor Aisling Capital II LP
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Aisling Capital II LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2019-02-11 13G/A CDTX / Cidara Therapeutics, Inc. 1,027,843 1,027,843
2018-08-30 13G/A VRAY / ViewRay Inc. 7,461,923 3,751,334
2018-02-07 13G/A ESPR / Esperion Therapeutics, Inc. 1,708,362 0
2018-01-24 13G VRAY / ViewRay Inc. 7,461,923
2017-11-16 13D/A ADMA / ADMA Biologics, Inc. 3,608,171 3,608,171
2017-01-25 13D/A ADMA / ADMA Biologics, Inc. 3,608,171 3,608,171
2017-01-24 13D/A ADMA / ADMA Biologics, Inc. 3,608,171
2016-05-17 13G CDTX / Cidara Therapeutics, Inc. 1,027,843
2016-03-09 13D/A MLNT / Melinta Therapeutics, Inc. 1,239,668
2016-03-09 13D/A CEMP / Cempra, Inc. 2,232,278 1,239,668
2016-02-05 13G/A ESPR / Esperion Therapeutics, Inc. 1,708,362
2015-05-18 13D/A MLNT / Melinta Therapeutics, Inc. 2,239,908
2015-05-18 13D/A CEMP / Cempra, Inc. 2,239,908
2014-02-07 13G ESPR / Esperion Therapeutics, Inc. 2,125,831
2013-10-23 13D/A ADMA / ADMA Biologics, Inc. 3,620,143
2012-02-22 13D ADMA / ADMA Biologics, Inc. 2,516,855
2012-02-15 13D MLNT / Melinta Therapeutics, Inc. 3,332,278